EpilepsyGTx announces a $10M fundraise to complete the CTA-enabling nonclinical package for lead program EPY201

Contributed by: Business Wire

Logo

Tags

Research

General Health

Professional Services

Pharmaceutical

Venture Capital

Genetics

Health Technology

Clinical Trials

Science

Biotechnology

Neurology

Health

Funding

More Like This

Egle Therapeutics Receives €9.3 Million in State Funding Under the “Innovations in Biotherapies and Bioproduction” Call for Projects from France 2030

EQT Life Sciences leads USD 75 million Series B in Atalanta Therapeutics, a biotech firm developing treatments for epilepsy and Huntington's disease

Release Therapeutics Secures CHF 3.3 Million in Seed Funding

Novotech Report Analyses Epilepsy Research Trends Finding More than 4,000 Clinical Trials Conducted Globally

Institute of Molecular and Clinical Ophthalmology Basel Spinout RhyGaze Closes USD 86 Million Series A Round to Further Novel Gene Therapy for Vision Restoration

Wyss Center for Bio and Neuroengineering Announces Venture with dEEGtal Insight: An Innovative Tool for Early Epilepsy Detection

Arctic Therapeutics Announces €26.5M Oversubscribed Series A Financing

EQT Life Sciences invests in Asceneuron, a neurodegeneration therapeutics company, as part of USD 100 million Series C financing round